Drugs / EDP1503
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03775850 | Dec 2018 → Jun 2021 | gastroesophageal cancer, metastasis from malignant tumor of colon, non-small cell lung carcinoma, renal cell carcinoma +2 | Evelo Biosciences, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03595683 | Oct 2018 → Jul 2025 | cutaneous melanoma | University of Chicago | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP1503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03775850 ↗ |
| Modality | Other / unclassified | “oral bacterial supplementation (EDP1503)” PMID 40830709 ↗ Aug 2025 |
| Route | Oral | “Taken by mouth twice daily.” NCT03595683 ↗ |